Helix BioPharma Corp. (HBPCF)
Helix BioPharma Corp. operates in the Biotechnology industry of the Healthcare sector, headquartered in Toronto, ON, CA. The stock last traded at $1.71, up 0.00% on the session, giving a market capitalisation of $130.6M. On trailing twelve-month figures it carries a trailing P/E of -38.64, a net margin of 0.0%. Its beta of -0.35 implies it has historically moved less than the broad market.
Helix BioPharma Corp. is a Canadian enterprise focused on immuno-oncology. The company's research and development efforts include L-DOS47, a drug candidate aimed at treating non-small cell lung cancer, and V-DOS47, which is designed to interact with vascular epithelial growth factor receptor 2 (VEGFR2). Helix has established collaborative agreements to further its research. One such partnership with Moffitt Cancer Center involves studying L-DOS47's pharmacodynamics and exploring the advantages of co-administering it with immune checkpoint inhibitors. A separate collaboration with University Hospital Tuebingen focuses on evaluating L-DOS47's therapeutic impact on CEACAM6-positive cancer models, employing advanced preclinical metabolic imaging techniques. The company's corporate headquarters are located in Toronto, Canada.
Helix BioPharma Corp. is most often compared with the following Healthcare names: